Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 2,690 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline solution Clear all

Conditions: Clostridium Infections
Interventions: GS-CDA1/MDX-1388, normal saline; Biological
Lead sponsor: MassBiologics; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 22
States / cities: Los Angeles, California • Oakland, California • Newark, Delaware + 18 more

Conditions: Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
Interventions: Depo-Medrol 40Mg/Ml Suspension for Injection, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Labor Induction, Cesarean Delivery
Interventions: Vaginal Misoprostol, Foley Balloon + Vaginal Misoprostol; Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions: Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colon Cancer, Rectal Cancer
Interventions: Floxuridine, Oxaliplatin, CPT-11; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid-use Disorder, Pain, Acute
Interventions: HYDROmorphone Injectable Solution, Ketamine, Placebos; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Influenza A, Influenza B
Interventions: Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Peripheral blood draw, Bone marrow aspirate, Buccal swab; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy; Drug · Diagnostic Test · Procedure
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infertility, Female
Interventions: G-CSF, Saline; Drug
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: HPV
Interventions: Gardasil-9, Lidocaine injection, Lorazepam; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Osteoarthritis of Knee
Interventions: Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo); Biological · Other
Lead sponsor: Britecyte; Network
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Baltimore, Maryland • Hagerstown, Maryland • Oxon Hill, Maryland + 4 more

Conditions: Heart Failure, Kidney Disease
Interventions: TRV120027, Normal Saline; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Durham, North Carolina + 1 more

Conditions: Spine Surgery, Back Pain
Interventions: High Dose Tranexamic acid, Low Dose Tranexamic acid, Tranexamic acid Topical, Normal saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: tocilizumab, Placebo; Drug
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hyponatremia
Interventions: 0.9 Normal Saline, 0.45 Normal Saline; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 6 Months to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Postpartum Depression
Interventions: Epidural saline + IV saline, Epidural morphine 3 mg + IV saline, Epidural morphine 3 mg + IV ketamine 0.3 mg/kg; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions: Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more

Conditions: Pain
Interventions: Buffered Lidocaine J-tip; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: Up to 90 Days
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft; Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: COVID-19
Interventions: Citicoline, Saline/Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Renal Cancer
Interventions: mannitol, placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Eosinophilic Asthma
Interventions: AVTX-002, Placebo; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Tucson, Arizona • Sacramento, California • Walnut Creek, California + 20 more

Conditions: Sepsis
Interventions: Ascorbic Acid, Normal Saline; Drug · Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, Delaware

Search by objective public record fields.

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression

Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer

Acute Pain Management in Patients on Opioid Replacement Therapy

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)

HPV Vaccine Reduced Dose

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

Combined IV and Topical TXA in Major Spine Surgery

AIDS 347: IL-6 Blockade in Treated HIV Infection

Reexamining Hypotonic Intravenous Fluid Use

Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Needle-Free Jet Injection of Lidocaine During Lumbar Puncture

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)

Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

High Dose Intravenous Ascorbic Acid in Severe Sepsis